Gilead Sciences, Inc. v. Rea

976 F. Supp. 2d 833, 2013 WL 5504370, 2013 U.S. Dist. LEXIS 144214
CourtDistrict Court, E.D. Virginia
DecidedOctober 3, 2013
DocketCivil Action No. 1:12-cv-1090
StatusPublished
Cited by2 cases

This text of 976 F. Supp. 2d 833 (Gilead Sciences, Inc. v. Rea) is published on Counsel Stack Legal Research, covering District Court, E.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gilead Sciences, Inc. v. Rea, 976 F. Supp. 2d 833, 2013 WL 5504370, 2013 U.S. Dist. LEXIS 144214 (E.D. Va. 2013).

Opinion

MEMORANDUM OPINION

LIAM O’GRADY, District Judge.

This matter comes before the Court on the parties’ cross-motions for summary [834]*834judgment (Dkt. Nos. 11 and 15). Plaintiff Gilead Sciences, Inc. (“Gilead”) asks the Court to find that the Defendant United States Patent and Trademark Office (“USPTO”) improperly calculated the patent term adjustment for the U.S. Patent No. 8,148,374 (“the '374 patent”). The cross-motions for summary judgment were opposed and argument on the matter was held on July 19, 2013. The facts in this case are undisputed and the legal disagreement between the parties is narrow, namely whether the USPTO’s construction of 35 U.S.C. § 154(b)(2)(C) is permissible. For the reasons that follow, the Court finds that the Defendant is entitled to judgment as a matter of law.

I. BACKGROUND

a. Statutory Framework

To acquire a patent, an applicant must submit an application with the USPTO. 35 U.S.C. § 111. The USPTO then examines the application to determine whether the applicant is entitled to a patent. Id. at § 131. If the USPTO determines that the application claims “two or more independent and distinct inventions,” the office may mandate that the application be restricted to one of the inventions. Id. at § 121. This is commonly referred to as a restriction requirement. Upon examination, notification of a restriction requirement must be sent to the applicant in the same manner as notification of a rejection or other objection to the application. Id. at § 132. If the USPTO determines at any time during the examination that an application is patentable it will likewise notify the applicant of the allowance. 37 C.F.R. § 1.311(a). Throughout the application process, an applicant has a duty to disclose “all information known to that individual to be material to patentability.” Id. at § 1.56(a). One way in which an applicant meets this duty to disclose is through the filing of an information disclosure statement (“IDS”).

The law governing the content and term of a patent is outlined in 35 U.S.C. § 154. Under § 154 a patent grant is issued for twenty years measured from the earliest filing date of the application. Id. Understanding that delays in the examination process might decrease the length of a patent term, Congress created provisions under which a patent owner can seek a patent term adjustment (“PTA”) for certain delays caused by the USPTO between the filing and issuance of a patent. Section 154(b)(1) outlines the general sources of delay for which a PTA can be sought. The first, commonly referred to as “A Delay,” allows for a patent term extension if the USPTO fails to provide a notification under § 132 or a notice of allowance within fourteen months of an application filing. 35 U.S.C. § 154(b)(1)(A)®. The second, commonly referred to as “B Delay,” allows for a one day extension for every day that the USPTO fails to issue a patent after three years have passed between the application and allowance dates. Id. at § 154(b)(1)(B). Finally, a “C Delay” allows a PTA for some types of delays excluded from the computation of a “B Delay.” Id. at § 154(b)(1)(C).

An applicant’s conduct also impacts the calculation of a PTA. In particular, a PTA is reduced by a period of time equal to the number of days which an applicant “failed to engage in reasonable efforts to conclude prosecution of the application.” Id. at § 154(b)(2)(C)®. Congress has explicitly directed the USPTO to issue regulations establishing what constitutes an applicant’s failure to engage in such reasonable efforts. Id. at § 154(b)(2)(C)(iii). The application of regulations promulgated by the USPTO pursuant to this mandate is the focus of the controversy before the Court.

[835]*835b. Material Facts

The facts in this case are not in dispute. On February 22, 2008, Gilead filed application number 12/036,124 with the USPTO. On November 18, 2009, the USPTO mailed a restriction requirement to Gilead, dividing the claims within the application into four groups of inventions and directing Gilead to select one for examination. On February 18, 2010, Gilead filed a response to the restriction requirement selecting one of the four groups for examination on the merits. On April 16, 2010, approximately two months after the USPTO received a response to the restriction requirement, Gilead filed a supplemental IDS. The IDS requested that the USPTO consider two additional co-pending patent applications owned by Gilead as part of the agency’s next office action. After further prosecution of the application, the USPTO issued a notice of allowance on July 29, 2011 and the '374 patent issued on April 3, 2012.

The parties agree that Gilead is entitled to a PTA as a result of USPTO’s failure to meet the timeliness requirements of § 154 in issuing the '374 patent. In calculating the appropriate PTA, the USPTO included 245 days of “A Delay” for the Office’s failure to meet the specific statutory response deadlines and 406 days of “B delay” for the Office’s failure to issue the patent within three years of the application’s filing date. Those 651 combined days were reduced by 35 days of overlapping delay, for a cumulative USPTO delay of 616 days. The USPTO further reduced the PTA by subtracting an additional 57 days for Gilead’s delay. This 57-day penalty was based on the period between Gilead’s initial reply to the restriction requirement and its filing of the additional IDS on April 16, 2010. With all of the delays accounted for, the USPTO calculated a total PTA of 559 days.1

On October 27, 2011, Gilead contested the 57-day assessment for applicant delay, arguing that its delay in filing the supplemental IDS should not be subtracted from the PTA. The USPTO rejected this argument on March 1, 2012, reasoning that “under 35 U.S.C. § 132, the first action mailed by the USPTO was the restriction requirement mailed November 18, 2009.” See Dkt. No. 16 at 12-13. Under this interpretation Gilead’s filing of a supplemental IDS after it had filed a response to the restriction requirement constituted a failure to engage in a reasonable effort to conclude prosecution as dictated by 37 C.F.R. § 1.704(c)(8).

Gilead filed the current action before the Court after the USPTO refused to reverse its PTA calculation for the '374 patent. In particular, Gilead complains that the USP-TO’s interpretation and application of § 154(b), which resulted in the 57-day assessment for applicant delay, was “arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with the law and in excess of statutory jurisdiction, authority, or limitation.” See Dkt. No. 1 at ¶ 28. See also 5 U.S.C. §§ 701-706.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gilead Sciences, Inc. v. Lee
778 F.3d 1341 (Federal Circuit, 2015)
Mohsenzadeh v. Lee
5 F. Supp. 3d 791 (E.D. Virginia, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
976 F. Supp. 2d 833, 2013 WL 5504370, 2013 U.S. Dist. LEXIS 144214, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gilead-sciences-inc-v-rea-vaed-2013.